MedTrace Logo

CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants

NCT07350837 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-16

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, and efficacy of AZD0120 in highly sensitized adult participants with ESKD awaiting kidney transplant-who, as assessed by investigators, are improbable desensitization through conventional treatments (e.g., plasmapheresis and immunoadsorption)- with or without living donors.

Conditions

  • Highly Sensitized Patients Awaiting Kidney Transplant

Interventions

DRUG

AZD0120

Treatment duration: A single dose of AZD0120 via IV infusion

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Gang Chen · Tongji Hospital, Tongji Medical Collage of Huazhong University of Science & Technology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-28
Primary Completion
2026-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07350837 on ClinicalTrials.gov